Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2009
Baloxavir marboxil for InfluenzaStatus:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) (TA732)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 October 2021
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Flu vaccination: increasing uptake (NG103)Product type:GuidanceProgramme:NICE guidelinePublished: 22 August 2018
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 September 2008